From the makers of Mounjaro, it's creating a stir on social media ...

When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...

European stocks fell Thursday as investors weighed ongoing concerns about the artificial-intelligence boom and data showing gains in business activity. The composite purchasing managers' index for the ...

In people with recently diagnosed type 2 diabetes and no prior cardiovascular disease, self-reported physical activity ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits totaling more than $2 billion circulated online in August 2025.

On May 12, Trump signed an executive order stating that U.S. consumers are being overcharged for prescription drugs and that “Americans must therefore have access to the most-favored-nation price.” ...

In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing financial toxicity and logistical barriers.

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...